Skip to main content
Delfa

← Trials/Trial dossier/NCT00733863

CompletedPhase 2

Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.

A 52-week,Multi-center,Randomized,Double-blind,Placebo-controlled,Parallel Group Study in Patients With Mild Alzheimer's Disease to Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106

Lead sponsor

Novartis

Asset

CAD106

Listed sites

4

Recruiting sites

-

Enrollment

27

actual

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•MMSE 20-26•AD symptomatic therapy: stable ≥6 weeks

Primary endpoint

•Safety/tolerability assessments at multiple timepoints

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDCCAD106A2201
NCT IDNCT00733863

Timeline

Milestones

Study start2008-07 (month precision)
Study first posted2008-08-13estimated
Primary completion2010-02actual (month precision)
Last update posted2020-02-11actual

Assets

Drug assets

CAD106

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age40 Years
Maximum age85 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Diagnosis of Mild Alzheimer's Disease
•Mini-Mental State Examination (MMSE) 20 to 26 at screening, untreated or on stable dose of cholinesterase inhibitor or memantine over the last 6 weeks

Exclusion criteria

•Previously participated in an AD vaccine study and received active treatment
•History or presence of an active autoimmune and/or with an acute or chronic inflammation, and/or clinically relevant atopic condition.
•History or presence of seizures and/or cerebrovascular disease.
•Presence of an other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression)

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
1
Other (unclassified)
1

Safety / tolerability / PK

1 endpoint
Primary/protocol endpoint

Safety/tolerability assessments at multiple timepoints including but not limited to screening, baseline, and through the end of the study to Week 52.

Time frame:52 weeks

descriptive

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Immune response, cognitive and functional assessments at multiple timepoints including but not limited to baseline and through the end of the study to Week 52.

Time frame:52 weeks

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.